143 related articles for article (PubMed ID: 6201759)
21. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.
Talmadge JE; Chirigos MA
Springer Semin Immunopathol; 1985; 8(4):429-43. PubMed ID: 3879016
[No Abstract] [Full Text] [Related]
22. Liver enzyme abnormalities after poly ICLC infusions.
Hess WA; Bever CT; McFarlin DE
Cancer Treat Rep; 1985 Nov; 69(11):1342. PubMed ID: 2418967
[No Abstract] [Full Text] [Related]
23. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
Puri SK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
[TBL] [Abstract][Full Text] [Related]
24. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)).
Rettenmaier MA; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Jul; 24(3):359-61. PubMed ID: 3721308
[TBL] [Abstract][Full Text] [Related]
25. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator.
Peters CJ; Reynolds JA; Slone TW; Jones DE; Stephen EL
Antiviral Res; 1986 Aug; 6(5):285-97. PubMed ID: 2429616
[TBL] [Abstract][Full Text] [Related]
26. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
27. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma.
Durie BG; Levy HB; Voakes J; Jett JR; Levine AS
J Biol Response Mod; 1985 Oct; 4(5):518-24. PubMed ID: 3935757
[TBL] [Abstract][Full Text] [Related]
28. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
29. Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.
Crane LR; Levy HB; Lerner AM
Antimicrob Agents Chemother; 1982 Mar; 21(3):481-5. PubMed ID: 7049075
[TBL] [Abstract][Full Text] [Related]
30. Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
Awasthi A; Mehrotra S; Bhakuni V; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1997 Jul; 17(7):419-23. PubMed ID: 9243375
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
Kende M
J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
[TBL] [Abstract][Full Text] [Related]
32. Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis.
Salazar AM; Engel WK; Levy HB
Arch Neurol; 1981 Jun; 38(6):382-3. PubMed ID: 7236070
[TBL] [Abstract][Full Text] [Related]
33. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits.
Levy HB; Lvovsky E
J Infect Dis; 1978 Jan; 137(1):78-81. PubMed ID: 624854
[TBL] [Abstract][Full Text] [Related]
34. Purification of carboxymethylcellulose decreases toxicity of poly ICLC in mice.
Bello J; O'Malley J; Granados E
J Interferon Res; 1985; 5(3):429-30. PubMed ID: 4056490
[TBL] [Abstract][Full Text] [Related]
35. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
36. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
37. Immunostimulants for malignant gliomas.
Butowski N
Neurosurg Clin N Am; 2010 Jan; 21(1):53-65. PubMed ID: 19944966
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid.
Droller MJ
J Urol; 1987 Feb; 137(2):202-6. PubMed ID: 3806804
[TBL] [Abstract][Full Text] [Related]
39. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.
Dillon PM; Petroni GR; Smolkin ME; Brenin DR; Chianese-Bullock KA; Smith KT; Olson WC; Fanous IS; Nail CJ; Brenin CM; Hall EH; Slingluff CL
J Immunother Cancer; 2017 Nov; 5(1):92. PubMed ID: 29157306
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.
Kende M; Paragas J; Salazar AM
Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
